60 Degrees Pharmaceuticals Inc
Research 60 Degrees Pharmaceuticals Inc (SXTP) on Bullrun: market cap USD 3.01M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSXTP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.01M
- Financial periodQ1 2026
- RevenueUSD 162.09K
- Net income-USD 2.09M
- Free cash flow-USD 2.78M
- Gross margin47.1%
Valuation Snapshot
latest market cap is USD 3.01M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.01M | -USD 7.37M | -USD 6.99M | 22.3% | -11.73 | USD 1.51M | USD 152.78K | USD 3.46M |
| FY2024 | USD 607.57K | -USD 7.95M | -USD 5.75M | 36.7% | -74.17 | USD 1.66M | USD 155.89K | USD 4.04M |
| FY2023 | USD 253.57K | -USD 3.77M | -USD 4.60M | -87.1% | -59.18 | USD 2.14M | USD 158.77K | USD 4.87M |
| FY2022 | USD 223.21K | -USD 6.18M | n/a | -93.7% | -2.61 | USD 264.87K | USD 16.86M | -USD 23.58M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.01M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.36M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.66M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 5.92M | n/a | n/a | n/a |
About 60 Degrees Pharmaceuticals Inc
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is 60 Degrees Pharmaceuticals Inc's market cap?
60 Degrees Pharmaceuticals Inc's market capitalization is USD 3.01M.
What does 60 Degrees Pharmaceuticals Inc do?
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever.